Background Background Aripiprazole is an
Aripiprazole is an atypical antipsychotic that is reported to atypical antipsychotic that is reported to be effective in the treatment of be effective in the treatment of schizophrenia. schizophrenia.
Aims Aims To investigate the effects of
To investigate the effects of aripiprazole on patients with aripiprazole on patients with schizophrenia and schizophrenia-like schizophrenia and schizophrenia-like psychoses by conducting a systematic psychoses by conducting a systematic review of randomised controlled trials review of randomised controlled trials (RCTs). (RCTs).
Method Method Database and manual
Database and manual searches and direct contact were used to searches and direct contact were used to identify relevant RCTs. identify relevant RCTs.
Results

Results We included10 randomised
We included10 randomised controlled studies (involving a total of 4125 controlled studies (involving a total of 4125 patients), but study attrition was large and patients), but study attrition was large and the standard of data reporting was poor. the standard of data reporting was poor. Compared with placebo, aripiprazole Compared with placebo, aripiprazole treatment was associated with a treatment was associated with a significant decrease in relapse rates, significant decrease in relapse rates, increased compliance with the study increased compliance with the study protocol, and a decrease in prolactin levels protocol, and a decrease in prolactin levels below the expected values.Compared below the expected values.Compared with risperidone, aripiprazole caused less with risperidone, aripiprazole caused less elevation of prolactin levels and less elevation of prolactin levels and less prolongation of the average QTc interval. prolongation of the average QTc interval.
Conclusions Conclusions Aripiprazole has been
Aripiprazole has been licensed despite the factthat few reliable licensed despite the factthat few reliable data on this drug are publicly available.It data on this drug are publicly available.It may be effective for treatment of may be effective for treatment of schizophrenia, but in terms of tolerability schizophrenia, but in terms of tolerability and global outcomes it shows little and global outcomes it shows little difference from existing antipsychotics. difference from existing antipsychotics.
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Atypical or second-generation antipsyAtypical or second-generation antipsychotics are said to differ from conventional chotics are said to differ from conventional or typical antipsychotics in terms of their or typical antipsychotics in terms of their effects on the positive and negative sympeffects on the positive and negative symptoms of schizophrenia and on cognition, toms of schizophrenia and on cognition, and in terms of their adverse effect proand in terms of their adverse effect profiles (Gelder files (Gelder et al et al, 2000) . Aripiprazole , 2000) . Aripiprazole is the prototype of a 'third generation' of is the prototype of a 'third generation' of antipsychotics -the so-called dopamineantipsychotics -the so-called dopamineserotonin-system stabilisers (Rivas-Vasquez, serotonin-system stabilisers (Rivas-Vasquez, 2003) . It is claimed to be at least as effec-2003) . It is claimed to be at least as effective as haloperidol in the treatment of tive as haloperidol in the treatment of positive and negative symptoms of schizopositive and negative symptoms of schizophrenia, and it may cause fewer adverse phrenia, and it may cause fewer adverse effects. Aripiprazole is reported to be useful effects. Aripiprazole is reported to be useful in all phases of schizophrenia, and to in all phases of schizophrenia, and to enhance cognitive function (Rivas-Vasquez, enhance cognitive function (Rivas-Vasquez, 2003) . In 2002 the drug was granted 2003). In 2002 the drug was granted approvable status by the US Food and Drug approvable status by the US Food and Drug Administration (FDA) for the treatment of Administration (FDA) for the treatment of schizophrenia (Dubitsky schizophrenia (Dubitsky et al et al, 2002) . . It has been included in recent guidelines on has been included in recent guidelines on schizophrenia treatment (American Psychischizophrenia treatment (American Psychiatric Association Work Group on Schizoatric Association Work Group on Schizophrenia, 2004) and it is licensed for use in phrenia, 2004) and it is licensed for use in several other countries, including the UK. several other countries, including the UK. We here report the findings of a systematic We here report the findings of a systematic review of randomised controlled trials review of randomised controlled trials (RCTs) of the effects of aripiprazole. (RCTs) of the effects of aripiprazole.
METHOD METHOD
Search strategy Search strategy
We searched the Cochrane Schizophrenia We searched the Cochrane Schizophrenia Group's register (August 2004) and we also Group's register (August 2004) and we also hand-searched relevant journals and conhand-searched relevant journals and conference proceedings, and used several grey ference proceedings, and used several grey literature sources (including pharmaceutiliterature sources (including pharmaceutical industry materials and non-systematic cal industry materials and non-systematic internet searches). In addition, we ininternet searches). In addition, we inspected the references cited in identified spected the references cited in identified studies for further trials and we examined studies for further trials and we examined the FDA website. We also contacted the FDA website. We also contacted relevant authors and the manufacturers of relevant authors and the manufacturers of aripiprazole (Bristol-Myers Squibb and aripiprazole (Bristol-Myers Squibb and Otsuka pharmaceuticals). Full details have Otsuka pharmaceuticals). Full details have been published previously (El-Sayeh & been published previously . .
Selection and inclusion criteria Selection and inclusion criteria
We reliably selected RCTs that compared We reliably selected RCTs that compared aripiprazole at any dose (the recommended aripiprazole at any dose (the recommended target dose is 10-15 mg/day, range 10-target dose is 10-15 mg/day, range 10-30 mg/day) with any other antipsychotics 30 mg/day) with any other antipsychotics or placebo in the treatment of people with or placebo in the treatment of people with schizophrenia or schizophrenia-like psyschizophrenia or schizophrenia-like psychoses. Our primary outcome was relapse, choses. Our primary outcome was relapse, but we also investigated a number of other but we also investigated a number of other outcomes, including death, mental state, outcomes, including death, mental state, cognitive functioning, adverse effects and cognitive functioning, adverse effects and quality of life. Before we viewed the data, quality of life. Before we viewed the data, we stipulated that outcome measures were we stipulated that outcome measures were to be categorised as short-term (up to 12 to be categorised as short-term (up to 12 weeks), medium-term (13-26 weeks) or weeks), medium-term (13-26 weeks) or long-term (over 26 weeks). We assessed long-term (over 26 weeks). We assessed study quality using the criteria described study quality using the criteria described in the in the Cochrane Reviewers' Handbook Cochrane Reviewers' Handbook 4.2.0 4.2.0 (Clarke & Oxman, 2003) . (Clarke & Oxman, 2003) .
Data analysis Data analysis
We analysed the data using RevMan We analysed the data using RevMan version 4. On the condition that more than 60% of On the condition that more than 60% of participants were accounted for with reparticipants were accounted for with respect to any given study outcome, everyone spect to any given study outcome, everyone allocated to the intervention was counted, allocated to the intervention was counted, whether they completed the follow-up or whether they completed the follow-up or not. It was assumed that those individuals not. It was assumed that those individuals who dropped out had a negative outcome who dropped out had a negative outcome (other than death). Continuous data were (other than death). Continuous data were synthesised using weighted mean differsynthesised using weighted mean difference. Statistical heterogeneity was assessed ence. Statistical heterogeneity was assessed by inspecting the relevant graph and was by inspecting the relevant graph and was supplemented using the supplemented using the I I-squared statistic -squared statistic (Higgins (Higgins et al et al, 2003) . If inconsistency was , 2003) . If inconsistency was high ( high (4 475%), the data were not pooled, 75%), the data were not pooled, but were presented separately and the but were presented separately and the reasons for heterogeneity were investigated. reasons for heterogeneity were investigated.
RESULTS RESULTS
We identified over 400 citations, of which We identified over 400 citations, of which 54 reported 10 relevant studies (Table 1) . 54 reported 10 relevant studies (Table 1 ). All of these 10 studies were randomised, All of these 10 studies were randomised, and all but one (Kern and all but one (Kern et al et al, 2001) were , 2001) were double-blind. However, none of them made double-blind. However, none of them made the method of randomisation explicit or the method of randomisation explicit or tested masking. Consequently they all carry tested masking. Consequently they all carry a moderate risk of bias and may therefore a moderate risk of bias and may therefore overestimate the positive effects of overestimate the positive effects of 1 0 2 1 0 2 B R I T I S H J O UR N A L O F P SYC HI AT RY B R I T I S H J O UR N A L O F P S YC H I AT RY (2 0 0 6), 18 9, 10 2^10 8 . doi : 10 .119 2 / bjp.18 9. 2 .10 2 ( 2 0 0 6 ) , 1 8 9, 1 0 2^1 0 8 . d o i : 1 0 .11 9 2 / b j p .1 8 9. 2 .1 0 2 AUTHOR'S PROOF AUTHOR'S PROOF AUTHOR'S PROOF AUTHOR'S PROOF , 2002) participants. Most of the participants were male inMost of the participants were male inpatients in their thirties or forties. The patients in their thirties or forties. The majority had well-defined diagnoses of majority had well-defined diagnoses of schizophrenia with little comorbidity. Such schizophrenia with little comorbidity. Such individuals represent a minority of patients individuals represent a minority of patients in everyday care. However, we would also in everyday care. However, we would also like to point out that there is variation in like to point out that there is variation in the clinical condition of the patients who the clinical condition of the patients who were randomised in the different studies. were randomised in the different studies. Although the majority of the participants Although the majority of the participants were noted to have had an acute relapse were noted to have had an acute relapse of schizophrenia, in some studies the partiof schizophrenia, in some studies the participants had chronic stable schizophrenia cipants had chronic stable schizophrenia or treatment-resistant schizophrenia. Any or treatment-resistant schizophrenia. Any interpretation of the findings of the metainterpretation of the findings of the metaanalyses must take into account this clinical analyses must take into account this clinical heterogeneity, and the fact that it could heterogeneity, and the fact that it could make our findings more rather than less make our findings more rather than less applicable to everyday care. applicable to everyday care.
Aripiprazole was compared with plaAripiprazole was compared with placebo in 6 studies (encompassing a total cebo in 6 studies (encompassing a total of 1628 patients), with haloperidol in 4 of 1628 patients), with haloperidol in 4 studies ( studies (n n¼1913), with perphenazine in 1 1913), with perphenazine in 1 study ( study (n n¼300), with olanzapine in 2 300), with olanzapine in 2 studies ( studies (n n¼573) and with risperidone in 1 573) and with risperidone in 1 study ( study (n n¼301). Aripiprazole was given over 301). Aripiprazole was given over a wide range of doses (2-30 mg/day) a wide range of doses (2-30 mg/day) (Dubitsky (Dubitsky et al et al, 2002 We found no usable data on website. We found no usable data on service outcomes, general functioning, service outcomes, general functioning, behaviour, engagement with mental health behaviour, engagement with mental health services, satisfaction with treatment, services, satisfaction with treatment, economic outcomes or cognitive functioneconomic outcomes or cognitive functioning. Although relapse was the primary outing. Although relapse was the primary outcome measure for this review, only one come measure for this review, only one study that compared aripiprazole treatment study that compared aripiprazole treatment with placebo (Carson with placebo (Carson et al et al, 2002 (Carson et al et al, ) provided , 2002 ) provided data on this outcome, and relapse in that data on this outcome, and relapse in that study was defined by changes in rating scale study was defined by changes in rating scale scores, not by re-hospitalisation rates as are scores, not by re-hospitalisation rates as are commonly used. Seven of the 10 studies commonly used. Seven of the 10 studies that were included reported data in terms that were included reported data in terms of both a last-observation-carried-forward of both a last-observation-carried-forward (LOCF) analysis and an observed-cases (LOCF) analysis and an observed-cases analysis (where observed cases are defined analysis (where observed cases are defined as those who completed the trial). We could as those who completed the trial). We could not use the LOCF data because of the high not use the LOCF data because of the high drop-out rates reported in the studies as drop-out rates reported in the studies as well as the tendency to report mean figures well as the tendency to report mean figures without providing a measure of variance. without providing a measure of variance.
More participants who were allocated More participants who were allocated to aripiprazole completed the studies comto aripiprazole completed the studies compared with those allocated placebo pared with those allocated placebo ( (n n¼1658, 6 RCTs, RR (leaving study for 1658, 6 RCTs, RR (leaving study for any reason) any reason)¼0.68, 95% CI 0.55-0.86; 0.68, 95% CI 0.55-0.86; NNT NNT¼4, 95% CI 6-11). However, 4, 95% CI 6-11). However, 1 0 5 1 0 5 AUTHOR'S PROOF AUTHOR'S PROOF Fig. 1 ). In total, 52% of participants left see Fig. 1 ). In total, 52% of participants left these 5 studies early. If an LOCF analysis these 5 studies early. If an LOCF analysis were to have been used, this would have were to have been used, this would have meant that large assumptions would have meant that large assumptions would have to be made about the outcomes of over half to be made about the outcomes of over half the participants. Before we viewed the data, the participants. Before we viewed the data, we had stated that making such we had stated that making such assumptions for over 40% of participants assumptions for over 40% of participants rendered the outcomes impossible to interrendered the outcomes impossible to interpret. In the comparison with the other pret. In the comparison with the other atypical antipsychotic medications, 53% atypical antipsychotic medications, 53% of the patients who were allocated aripipraof the patients who were allocated aripiprazole treatment left the studies before the zole treatment left the studies before the end of the trial, compared with 58% of end of the trial, compared with 58% of the patients in the comparison groups the patients in the comparison groups ( (n n¼618, There were significantly fewer relapses There were significantly fewer relapses among patients who were given aripipamong patients who were given aripiprazole compared with those who were razole compared with those who were allocated placebo (relapse by 12 weeks: allocated placebo (relapse by 12 weeks: n n¼310, 1 RCT, RR 310, 1 RCT, RR¼0.59, 95% CI 0.45-0.59, 95% CI 0.45-0.77; NNT 0.77; NNT¼5, 95% CI 4-8; relapse by 5, 95% CI 4-8; relapse by 26 weeks: 26 weeks: n n¼310, 1 RCT, RR 310, 1 RCT, RR¼0.66, 0.66, 95% CI 0.53-0.81; NNT 95% CI 0.53-0.81; NNT¼5, 95% CI 4-5, 95% CI 4-8). This study defined relapse as either a 8). This study defined relapse as either a Clinical Global Impression (CGI; Guy, Clinical Global Impression (CGI; rating of minimally worse, or a Posi-1976) rating of minimally worse, or a Positive and Negative Syndrome Scale (PANSS; tive and Negative Syndrome Scale (PANSS; Kay Kay et al et al, 1987) rating of moderately severe , 1987) rating of moderately severe on hostility or uncooperativeness on two on hostility or uncooperativeness on two successive days, or an increase in total successive days, or an increase in total PANSS score of 20% or more compared PANSS score of 20% or more compared with the score at randomisation (Carson with the score at randomisation (Carson et al et al, 2002) . Patients who were allocated , 2002). Patients who were allocated aripiprazole were at less risk of poor comaripiprazole were at less risk of poor compliance with the study protocol because of pliance with the study protocol because of lack of efficacy, deterioration or psychosis. lack of efficacy, deterioration or psychosis. Significantly fewer patients who were alloSignificantly fewer patients who were allocated aripiprazole compared with those cated aripiprazole compared with those who were given placebo experienced this who were given placebo experienced this deterioration ( deterioration (n n¼1348, 5 RCTs, RR (by 1348, 5 RCTs, RR (by about 12 weeks) about 12 weeks) ¼0.66, 95% CI 0.49-0.66, 95% CI 0.49-0.88; NNT 0.88; NNT¼15, 95% CI 10-41). No differ-15, 95% CI 10-41). No difference was found between aripiprazole and ence was found between aripiprazole and either the typical antipsychotic drugs haloeither the typical antipsychotic drugs haloperidol and perphenazine ( peridol and perphenazine (n n¼2213, 5 2213, 5 RCTs, RR RCTs, RR¼1.1, 95% CI 0.91-1.32) or 1.1, 95% CI 0.91-1.32) or the atypical antipsychotic drugs olanzapine the atypical antipsychotic drugs olanzapine and risperidone for this same global and risperidone for this same global outcome ( outcome (n n¼618, 2 RCTs, RR 618, 2 RCTs, RR¼1.76, 1.76, 95% CI 0.87-3.54). 95% CI 0.87-3.54).
Aripiprazole had a favourable effect Aripiprazole had a favourable effect compared with placebo on a range of adcompared with placebo on a range of adverse effects, including headache ( verse effects, including headache (n n¼615, 615, 2 RCTs, RR 2 RCTs, RR¼1.04, 95% CI 0.76-1.43), 1.04, 95% CI 0.76-1.43), anxiety ( anxiety (n n¼615, 2 RCTs, RR 615, 2 RCTs, RR¼0.86, 95% 0.86, 95% CI 0.53-1.39), weight gain ( CI 0.53-1.39), weight gain (n n¼615, 2 615, 2 RCTs, RR RCTs, RR¼2.64, 95% CI 0.70-9.95), 2.64, 95% CI 0.70-9.95), extrapyramidal side-effects ( extrapyramidal side-effects (n n¼615, 2 615, 2 RCTs, RR RCTs, RR¼1.63, 95% CI 0.15-17.55) 1.63, 95% CI 0.15-17.55) and changes in QTc interval (aripiprazole and changes in QTc interval (aripiprazole 20 mg) ( 20 mg) (n n¼204, 1 RCT, 95% CI 204, 1 RCT, 95% CI 7 73.19 3.19 to 9.19). Aripiprazole did appear to be to 9.19). Aripiprazole did appear to be significantly superior to placebo in terms significantly superior to placebo in terms of the number of patients who showed a of the number of patients who showed a rise in serum prolactin level to at least rise in serum prolactin level to at least 23 ng/ml in one short study ( 23 ng/ml in one short study (n n¼305, 305, RR RR¼0.32, 95% CI 0.13-0.81; NNT 0.32, 95% CI 0.13-0.81; NNT¼14, 14, 95% CI 11-50) (Potkin 95% CI 11-50) (Potkin et al et al, 2003) . . Because of high drop-out rates and undercause of high drop-out rates and underreporting in the included studies, we could reporting in the included studies, we could only derive data on adverse effects for aripionly derive data on adverse effects for aripiprazole compared with typical antipsychoprazole compared with typical antipsychotics from a single study which used a tics from a single study which used a perphenazine control (Kane perphenazine control (Kane et al et al, 2003) . , 2003). The results suggest that there is little signifThe results suggest that there is little significant difference in specific adverse effects icant difference in specific adverse effects between aripiprazole and this typical antibetween aripiprazole and this typical antipsychotic (Fig. 2) , apart from the finding psychotic (Fig. 2) , apart from the finding 1 0 6 1 0 6 AUTHOR'S PROOF AUTHOR'S PROOF Comparison of aripiprazole with placebo in participants who left the study early for any reason. that patients who were allocated aripiprathat patients who were allocated aripiprazole required less antiparkinsonian medizole required less antiparkinsonian medication (NNT cation (NNT¼4, 95% CI 3-5) and more 4, 95% CI 3-5) and more often experienced insomnia (NNH often experienced insomnia (NNH¼4, 4, 95% CI 3-9). No outcomes were available 95% CI 3-9). No outcomes were available to allow comparison of aripiprazole with to allow comparison of aripiprazole with typical antipsychotic medication with retypical antipsychotic medication with regard to changes in the QTc interval. gard to changes in the QTc interval.
When combined, two trials that comWhen combined, two trials that compared aripiprazole with other atypical pared aripiprazole with other atypical antipsychotics failed to show any difference antipsychotics failed to show any difference between the new drug and the other atypibetween the new drug and the other atypicals for the outcome of weight gain of cals for the outcome of weight gain of 7% or more above baseline ( 7% or more above baseline (n n¼556, 556, RR RR¼0.49, 95% CI 0.12-1.94) (Fig. 3) . 0.49, 95% CI 0.12-1.94) (Fig. 3) . Aripiprazole treatment at a dose of 20 mg/ Aripiprazole treatment at a dose of 20 mg/ day resulted in significantly less change in day resulted in significantly less change in QTc interval than risperidone in the short QTc interval than risperidone in the short term ( term (n n¼200, 1 RCT, weighted mean dif-200, 1 RCT, weighted mean difference ference 7 76.0, 95% CI 6.0, 95% CI 7 713.11 to 1.11), 13.11 to 1.11), and this remained true for higher doses of and this remained true for higher doses of aripiprazole. Treatment with aripiprazole aripiprazole. Treatment with aripiprazole was associated with significantly less risk was associated with significantly less risk of an increase in prolactin levels above of an increase in prolactin levels above 23 ng/ml than 6 mg/day of risperidone 23 ng/ml than 6 mg/day of risperidone ( (n n¼301, RR 301, RR¼0.04, 95% CI 0.02-0.08; 0.04, 95% CI 0.02-0.08; NNT NNT¼2, 95% CI 1-2.5), but the clinical 2, 95% CI 1-2.5), but the clinical implications of this are unclear. Overall implications of this are unclear. Overall there appeared to be few differences bethere appeared to be few differences between aripiprazole and other atypical antitween aripiprazole and other atypical antipsychotics, but more well-designed and psychotics, but more well-designed and adequately reported studies are needed to adequately reported studies are needed to demonstrate whether this is indeed the case. demonstrate whether this is indeed the case.
Eight people who were allocated aripiEight people who were allocated aripiprazole are known to have died in openprazole are known to have died in openlabel extension arms of two of the studies label extension arms of two of the studies (total (total n n¼834) (Carson 834) (Carson et al et al, 2000; Adson , 2000; Adson et al et al, 2002) . However, the authors note , 2002). However, the authors note that the causes of these eight deaths that the causes of these eight deaths included suicide. The included suicide. The people who were people who were randomised in these two trials were experirandomised in these two trials were experiencing an acute relapse of schizophrenia, encing an acute relapse of schizophrenia, and this may partly explain the observed and this may partly explain the observed mortality figures. None of these deaths ocmortality figures. None of these deaths occurred in the randomised controlled phase curred in the randomised controlled phase of these trials. of these trials.
DISCUSSION DISCUSSION
Limitations of data on deaths Limitations of data on deaths
Despite the eight deaths reported in the reDespite the eight deaths reported in the results section above, this research finding sults section above, this research finding has not been widely disseminated. Also, has not been widely disseminated. Also, on the FDA website, a number of addion the FDA website, a number of additional deaths are reported in those known tional deaths are reported in those known to be allocated to aripiprazole in various to be allocated to aripiprazole in various trials. However, we have been informed trials. However, we have been informed by the pharmaceutical company in question by the pharmaceutical company in question that these deaths did not occur in trials rethat these deaths did not occur in trials relevant to this review. We are in continued levant to this review. We are in continued dialogue with Bristol-Myers Squibb, and dialogue with Bristol-Myers Squibb, and hope to gain further clarification on these hope to gain further clarification on these and other data. Not disseminating clear and other data. Not disseminating clear information regarding these people's outinformation regarding these people's outcome, we argue, breaks that unspoken come, we argue, breaks that unspoken contract that occurs between researchers contract that occurs between researchers and trial participants at the point of gaining and trial participants at the point of gaining informed consent. Formalising the contract informed consent. Formalising the contract of informed consent, public registration of of informed consent, public registration of all future trials before randomisation and all future trials before randomisation and clearer dissemination of trial data are all clearer dissemination of trial data are all essential steps in rectifying this situation. essential steps in rectifying this situation.
Other data limitations Other data limitations
Many of the data used in this review were obMany of the data used in this review were obtained from conference proceedings and postained from conference proceedings and posters, making extraction difficult and doubleters, making extraction difficult and doublecounting likely. No serious published attempt counting likely. No serious published attempt was made to give each study a unique was made to give each study a unique identifier. A total of 16 relevant studies, identifier. A total of 16 relevant studies, including a number of Japanese phase II including a number of Japanese phase II and phase III studies, were only available and phase III studies, were only available on the FDA website and could not be inon the FDA website and could not be included because the data were incomplete cluded because the data were incomplete (Dubitsky (Dubitsky et al et al, 2002) . Therefore we can-, 2002). Therefore we cannot include these studies without the exnot include these studies without the express assistance of the pharmaceutical press assistance of the pharmaceutical companies who own the material. Multiple companies who own the material. Multiple requests for further information on the requests for further information on the highlighted FDA-identified trials have been highlighted FDA-identified trials have been made by telephone, by e-mail and in person. made by telephone, by e-mail and in person. It is unlikely that patients who gave their It is unlikely that patients who gave their informed consent would have understood informed consent would have understood that their results would remain undisclosed that their results would remain undisclosed and would therefore not help to inform the and would therefore not help to inform the care of other people with schizophrenia. care of other people with schizophrenia.
These studies were not designed to proThese studies were not designed to provide results of great relevance to everyday vide results of great relevance to everyday care. They were designed in line with the care. They were designed in line with the stipulations of the drug regulatory authoristipulations of the drug regulatory authorities. The majority of trials included wellties. The majority of trials included welldefined study participants with little defined study participants with little comorbidity. The typical antipsychotic comorbidity. The typical antipsychotic drugs of comparison reported in this review drugs of comparison reported in this review were occasionally of such a nature or used were occasionally of such a nature or used at such a dose that they distanced these at such a dose that they distanced these trials even further from everyday practice. trials even further from everyday practice. The outcomes are remarkably few in The outcomes are remarkably few in number, of limited duration and poorly number, of limited duration and poorly reported, and they take little account of reported, and they take little account of the CONSORT statement (Moher the CONSORT statement (Moher et al et al, , 2001 ), or else they carry such assumptions 2001), or else they carry such assumptions as to render them meaningless. Accordas to render them meaningless. Accordingly, findings from these studies are ingly, findings from these studies are difficult to translate into meaningful decidifficult to translate into meaningful decisions about patient care. Where complete sions about patient care. Where complete data on adverse effects are available, the dedata on adverse effects are available, the decision to report only events which occur in cision to report only events which occur in at least 5-10% of participants means that at least 5-10% of participants means that rare serious adverse events are not rerare serious adverse events are not recorded. Large amounts of data could not corded. Large amounts of data could not be used for this review, partly because of be used for this review, partly because of the poor quality of reporting. Many studies the poor quality of reporting. Many studies failed to provide standard deviations when failed to provide standard deviations when reporting mean changes in a particular outreporting mean changes in a particular outcome measure. Other studies failed to recome measure. Other studies failed to report outcomes in more than 40% of port outcomes in more than 40% of randomised patients. In accordance with randomised patients. In accordance with our protocol (see above section on data anaour protocol (see above section on data analysis), we believe that including data from lysis), we believe that including data from this population would involve making too this population would involve making too many assumptions about final outcomes, many assumptions about final outcomes, 1 0 7 1 0 7 AUTHOR'S PROOF AUTHOR'S PROOF and that these data should not be used until and that these data should not be used until further information has been obtained. further information has been obtained.
Recommendations Recommendations and implications and implications
We recommend that there should be greater We recommend that there should be greater compliance with CONSORT guidance in fucompliance with CONSORT guidance in future studies. The allocation of unique study ture studies. The allocation of unique study identifier numbers to minimise confusion, identifier numbers to minimise confusion, performing an intention-to-treat analysis on performing an intention-to-treat analysis on all outcomes, and clear presentation of all all outcomes, and clear presentation of all study data are critical to this process. study data are critical to this process. This systematic review suggests that This systematic review suggests that aripiprazole does not differ significantly aripiprazole does not differ significantly from some typical or other atypical antipsyfrom some typical or other atypical antipsychotics in terms of several global outcomes chotics in terms of several global outcomes and adverse effects. However, it does not and adverse effects. However, it does not appear to cause hyperprolactinaemia, an appear to cause hyperprolactinaemia, an adverse effect that is commonly seen with adverse effect that is commonly seen with the typical antipsychotics and even with the typical antipsychotics and even with some of the other atypical antipsychotics. some of the other atypical antipsychotics. There appeared to be no significant differThere appeared to be no significant difference in prolongation of the QTc interval ence in prolongation of the QTc interval compared with placebo, but there was compared with placebo, but there was less change in the QTc interval in one less change in the QTc interval in one study that compared aripiprazole with study that compared aripiprazole with other atypical antipsychotics (risperidone, other atypical antipsychotics (risperidone, n n¼200 patients). No data were available 200 patients). No data were available on the effect on QTc interval compared on the effect on QTc interval compared with typical antipsychotics. Aripiprazole with typical antipsychotics. Aripiprazole may cause more insomnia than typical antimay cause more insomnia than typical antipsychotics, but is perhaps also associated psychotics, but is perhaps also associated with less need for antiparkinsonian mediwith less need for antiparkinsonian medication. However, the authors acknowledge cation. However, the authors acknowledge that because of the lack of available evithat because of the lack of available evidence, and the limited numbers of comdence, and the limited numbers of comparator drugs that were used in these parator drugs that were used in these trials, further studies using a wider range trials, further studies using a wider range of comparator drugs may be required beof comparator drugs may be required before the results can be generalised to an fore the results can be generalised to an antipsychotic class (either typical or atypiantipsychotic class (either typical or atypical) as a whole. cal) as a whole.
Aripiprazole is an interesting compound Aripiprazole is an interesting compound with a novel mechanism of antipsychotic with a novel mechanism of antipsychotic action, but its real effects are unclear, partly action, but its real effects are unclear, partly as a consequence of the requirements of as a consequence of the requirements of both the regulatory authorities and the both the regulatory authorities and the pharmaceutical industry. This review pharmaceutical industry. This review effectively demonstrates why large, long, effectively demonstrates why large, long, well-designed, well-conducted and adewell-designed, well-conducted and adequately reported pragmatic RCTs should quately reported pragmatic RCTs should be part of the regulatory authority's be part of the regulatory authority's requirements. It also illustrates the way in requirements. It also illustrates the way in which clinicians, recipients of care, policy which clinicians, recipients of care, policy makers and even those who work in the makers and even those who work in the pharmaceutical industry are compromised pharmaceutical industry are compromised by the limitations of using explanatory by the limitations of using explanatory trials as the sole basis for allowing a drug trials as the sole basis for allowing a drug to be given a national licence. to be given a national licence.
